Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

Stifel initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $20.00

RBC Capital Mkts initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $22.00

Leerink Partners initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $19.00

Chardan Capital Markets initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $23.00

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac d

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platfo

Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response Frataxin expression and LVMI improvement exceed co-primary target thresholds for planned registrational study LX2006 generally well tolerated with no signs of complement activation or other immunogenicity to date Company to host w

Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in s

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-b

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused on a discussion of Duchenne muscular dystrophy ("DMD") by Key Opinion Leaders ("KOLs") in the space. Registration for the event is available at the following link: https://propthink.clickmeeting.com/duchenne-kol-investor-call/register The live event, hosted by PropThink Digital Conferences (the "Host"), will take place on Wednesday, December 4, 2024, at 2:00 pm ET, and focus on three crucial to

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

S-3/A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

S-3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries.   "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N